Lightnews — Scholar-powered news

Reposted by Gabriele Picco

Inigo Martincorena @imartincorena.bsky.social · 6h

Our latest work is out in Nature today. In this paper, we introduce an improved version of NanoSeq, a duplex sequencing protocol with <5 errors per billion bp in single DNA molecules, and use it to study the somatic mutation landscape of oral epithelium in >1000 people www.nature.com/articles/s41...

Somatic mutation and selection at population scale - Nature

A new version of nanorate DNA sequencing, with an error rate lower than five errors per billion base pairs and compatible with whole-exome and targeted capture, enables epidemiological-scale studies of somatic mutation and selection and the generation of high-resolution selection maps across coding and non-coding sites for many genes.

www.nature.com

3 19 39

Reposted by Gabriele Picco

ralucagordan.bsky.social @ralucagordan.bsky.social · 5d

I'm very pleased to announce the official publication of our lab's paper "DNA mutagenesis driven by transcription factor competition with mismatch repair" in today's issue of Cell! www.cell.com/cell/abstrac...

DNA mutagenesis driven by transcription factor competition with mismatch repair

Competition between transcription factors and mismatch repair machinery drives localized hypermutation at regulatory elements, with implications for cancer and genome evolution.

www.cell.com

2 12 57

Reposted by Gabriele Picco

Mathew Garnett @mgarnett.bsky.social · 18d

The Garnett Lab is excited to launch DepMap Miner, a new tool to explore cancer dependency data!
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.

Start mining data now: dataminer.depmap.sanger.ac.uk

2 23 55

Reposted by Gabriele Picco

Barbara Marte @barbmarte.bsky.social · 27d

new out in Nature www.nature.com/articles/s41...

Fluctuating DNA methylation tracks cancer evolution at clinical scale - Nature

Cancer evolutionary dynamics are quantitatively inferred using a method, EVOFLUx, applied to fluctuating DNA methylation.

www.nature.com

1 3

Reposted by Gabriele Picco

Trevor Graham @trevorgraham.bsky.social · Jul 17

Goldschmidt's hopeful monsters in cancer: single cell DNAseq shows whole genome doubling (WGD) is an ongoing and frequent mutational process in ovarian cancer. www.nature.com/articles/s41... beautiful work from @sohrabshah.bsky.social and team

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer - Nature

A single-cell sequencing study using more than 30,000 tumour genomes from human ovarian cancers shows that whole-genome doubling is an ongoing mutational process that drives tumour evolution and disru...

www.nature.com

12 31

Reposted by Gabriele Picco

Christian Frezza @frezzalab.bsky.social · Jul 4

www.nature.com/articles/s41...

Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers

Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers - Nature Genetics

The paralogs cytidine diphosphate diacylglycerol synthase 1 and 2 form a potentially targetable synthetic lethal relationship in mesenchymal-like cancers that involves disruption of lipid metabolism.

www.nature.com

2 4

Reposted by Gabriele Picco

Kevin Monahan @kevinmonahan.bsky.social · Jun 10

On behalf of InSiGHT, we are delighted to welcome you to the #InSiGHT2026 meeting in Singapore, taking place from 4 – 7 March 2026 #LynchSyndrome #Polyposis @cgaigc.com @stmarksgenomics.bsky.social

insight2026.org

InSIGHT 2026

REGISTRATION NOW OPEN Register NowCall for Abstracts Now Open! Submit Your AbstractWelcome MessageWelcome to Singapore, Selamat Datang, 欢迎, வருக வருக. On behalf of InSIGHT, we are delighted to invite....

insight2026.org

3 2

Reposted by Gabriele Picco

European Research Council (ERC) @erc.europa.eu · Jun 2

Planning to apply for #research #funding from the ERC?

From the next application rounds, expect changes to the:

• proposal structure
• evaluation process
• extra funding you can request
• eligibility for Starting & Consolidator #Grants (from 2027)

More 👇 europa.eu/!RPHWvv

Changes to the 2026 and 2027 Work Programmes

With the launch of the competitions for grants under ERC Work Programme 2026 in July of this year, several changes to the submission of applications and the evaluation of proposals will apply. The mai...

europa.eu

3 100 150

Reposted by Gabriele Picco

Cansu Dinçer @cansudincer.bsky.social · May 22

🚨 Excited to share our latest preprint!
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor

bioRxivpreprint @biorxivpreprint.bsky.social · May 20

BEstimate: a computational tool for the design and interpretation of CRISPR base editing experiments https://www.biorxiv.org/content/10.1101/2025.05.19.654892v1

1 5 8

Reposted by Gabriele Picco

Omer Ali Bayraktar @bayraktarlab.bsky.social · May 16

How does tumour heterogeneity arise? How can we predict cancer cell plasticity? In 2 new studies, we trace #glioblastoma heterogeneity to a spatial cancer cell trajectory w. multimodal cell atlassing bit.ly/4mkrWgs & predict plasticity w. snRNA/ATAC+deep learning bit.ly/3FbI6Ic 🧵

6 31 73

Gabriele Picco @gabrielepicco.bsky.social · Apr 29

Great to see WRN featured in the #AACR25 Special Session on 'Bringing Science to the Clinic: Overcoming Hurdles for Therapeutic Translation.' Grateful to Tim Yap for highlighting our past and ongoing work!

1 4

Gabriele Picco @gabrielepicco.bsky.social · Apr 28

Great talk by Yanhua Rao at #AACR2025 on GSK’s new clinical WRN inhibitor. Proud to see our unpublished data spotlighted for revealing new MoA insights. Exciting times ahead! @mgarnett.bsky.social

2 4

Gabriele Picco @gabrielepicco.bsky.social · Apr 25

A fantastic collaboration with Emile Voest’s lab at NKI, the new @mattcoelho.bsky.social group. WG CRISPR screens in MSI organoids co-cultured with autologous reactive T cells! Amazing work from Alex Watterson! New preprint here: www.biorxiv.org/content/10.1...
#Organoids #Immunotherapy #CRISPR #MSI

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

www.biorxiv.org

3

Gabriele Picco @gabrielepicco.bsky.social · Apr 25

6 years from WRN:MSI discovery to first-in-human trial data — incredible. A fantastic journey. Now, hoping for exciting news at AACR and real impact for patients real soon! #CancerResearch

Gabriele Picco @gabrielepicco.bsky.social · Apr 25

Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality

1 1 10

Reposted by Gabriele Picco

Kevin Monahan @kevinmonahan.bsky.social · Apr 25

Promising early safety and immunogenicity data from the Nous-209 Lynch Syndrome vaccine presented at AACR this month aacrjournals.org/cancerres/ar...

Abstract 6427: Nous-209 off-the-shelf neoantigen immunotherapy induces robust neoantigen T cell response with the potential to intercept cancer in Lynch syndrome carriers

Abstract. Cancer interception represents a new approach, aimed at targeting precancerous lesions and therefore preventing cancer occurrence. Lynch syndrome (LS) is one of the most prevalent hereditary...

aacrjournals.org

3 2

Reposted by Gabriele Picco

Matt Coelho @mattcoelho.bsky.social · Apr 22

Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

www.biorxiv.org

1 5 6

Gabriele Picco @gabrielepicco.bsky.social · Mar 24

Maurizio si prende il tempo. Ha scritto un libro che spiega il cancro e la ricerca con semplicità, rigore e responsabilità. Da leggere e regalare. Presenterà presto il libro in Italia. Non perdetevelo!

2

Gabriele Picco @gabrielepicco.bsky.social · Mar 24

Ho conosciuto @scaltritilab.bsky.social grazie ai suoi lavori, poi l'ho incontrato più volte. Circondato da colleghi e collaboratori, si è sempre fermato a parlare con me, condividendo idee e riflessioni sulla nostra ricerca.

1 2

Gabriele Picco @gabrielepicco.bsky.social · Mar 24

Non è facile parlare di cancro. Trovare le parole giuste senza banalizzare né spaventare, senza annoiare né essere troppo tecnici, non è facile. Parlarne con chiarezza è essenziale.

1 3

Gabriele Picco @gabrielepicco.bsky.social · Mar 24

Quando torno in Italia, mi chiedono spesso: "Di cosa ti occupi adesso?" o "A che punto siamo con la cura del cancro?" Domande semplici, risposte complesse – spesso taglio corto.

1 2

Reposted by Gabriele Picco

Ultan McDermott @ultanmcd.bsky.social · Mar 6

Please forward to any interested scientists - we're looking for a scientist to work in our functional genomics centre to find new cancer targets in Cambridge, UK. A mix of wet lab as well as computational skills a plus.
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...

Senior scientist – functional genomics

Senior scientist – functional genomics Location: Cambridge Salary: Competitive About AstraZeneca AstraZeneca is a global, science-led, and patient-focused biopharmaceutical company that focuses on the...

astrazeneca.wd3.myworkdayjobs.com

1 2

Reposted by Gabriele Picco

Elizabeth McKenna @elizsmckenna.bsky.social · Mar 4

Now online in Cancer Discovery: Single-Cell eQTL Mapping Reveals Cell Subtype-Specific Genetic Control and Mechanism in Malignant Transformation of Colorectal Cancer - by Can Chen, Yimin Cai, Wenlong Hu, Kai Tan, Zequn Lu, Xuanyu Zhu, Jianbo Tian, Xiaoping Miao & colleagues doi.org/10.1158/2159...

5 10

Reposted by Gabriele Picco

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · Mar 3

Work led by Syed Haider and our team at the @breastcancernow.bsky Toby Robins Research Centre @icr.ac.uk and funded by @cancerresearchuk.org

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · Mar 3

We show transcriptomic buffering of tumour suppressor loss via syn. lethal genes is not anecdotal but a cancer hallmark. Buffering also seen in BRCAness, predicts penetrant syn leth effects and outcome. @icr.ac.uk @cancerresearchuk.org @breastcancernow.bsky.social www.nature.com/articles/s41...

The transcriptomic architecture of common cancers reflects synthetic lethal interactions - Nature Genetics

Tumor cells upregulate compensatory buffering genes following tumor suppressor loss. These genes may represent new synthetic lethal partners that could be harnessed therapeutically.

www.nature.com

2 2

Reposted by Gabriele Picco

Matt Coelho @mattcoelho.bsky.social · Feb 28

Today in BJC Reports, we summarise the outcomes from a multidisciplinary workshop focused on addressing cancer drug resistance.
www.nature.com/articles/s44...

Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance - BJC Reports

BJC Reports - Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance

www.nature.com

1 2 5